CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04255381
NCT04255381N/ACompleted
CompareCT.gov

Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID)

Yale University·interventional·Posted Feb 5, 2020·Updated Jun 1, 2022

In Brief

A clinical study evaluating Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) for Type1 Diabetes. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The aim of this clinical study is to determine the feasibility, safety, and preliminary effectiveness of the Zone-Model Predictive Control Artificial Pancreas (ZMPC\_AP) system in pediatric subjects with type 1 diabetes in an ambulatory semi-supervised environment over a short duration of 3 days and 2 nights, or up to 60 hours.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1 Diabetes
CountriesUnited States
CollaboratorsHarvard University

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 5, 2020
Enrollment StartOct 1, 2018
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.4 years ago

Interventions

Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)device

Zone-Model Predictive Control Artificial Pancreas (ZMPC\_AP)